WITHDRAWN: High SLC7A11 Expression Is Correlated With Poor Prognosis and Associated With Ferroptosis in Ovarian Cancer 

Abstract

The current treatments of ovarian cancer (OC) do not yield satisfactory outcomes. Hence, it is necessary to find new treatment targets for OC. In this study, a comprehensive bioinformatic analysis was conducted to identify differentially expressed genes (DEGs) between OC and control tissues. Five datasets were downloaded from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were screened by comparing gene expression between OC and control tissues. Module analysis of DEGs was performed on the STRING database and GEPIA. Kaplan Meier plotter and GEPIA database analysis the overall survival. Finally, SLC7A11 was found to be is the hubgene. And we confirm that the protein expression of SLC7A11 was increased in OC tissues. Analysis of a variety of tumor gene databases showed that SLC7A11 gene regulated the processes of OC. The low mutation rate of the gene (which were of amplified type) and high mRNA expression were associated with poor prognosis of OC patients.Using erastin-treated ovarian cancer (OC) cell lines, we examined the relationship between ferroptosis and OC. Results showed that OC tissues contained higher malondialdehyde (MDA) levels than normal tissues. Unlike normal ovarian epithelial cells which are not sensitive to erastin, the OC cell line, ES-2 is very sensitive to erastin. Here, we found that ferrostatin-1 treatment increased levels of reactive oxygen species (ROS), malondialdehyde, and SLC7A11 protein expression. These results provide an important theoretical basis for further studies into the role of SLC7A11, the effective biomarker and potential drug target, in the occurrence and development of OC.